Examining Effects of Tysabri on Cognitive Fatigue Using fMRI

NCT ID: NCT04565431

Last Updated: 2024-02-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

25 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-03-19

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research study is to investigate the effectiveness of Tysabri on cognitive fatigue in persons with Relapsing-Remitting Multiple Sclerosis (RRMS). Cognitive fatigue is the kind of fatigue that occurs after intense mental concentration as after a session of problem solving.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The researchers aim is to investigate the effects of Tysabri on cognitive fatigue and on specific brain areas that have been shown to underlie cognitive fatigue in individuals with RRMS. The researchers will investigate the effects on the cognitive fatigue that develops during the performance of a demanding task and also on how cognitive fatigue changes as a function of duration of treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis, Relapsing-Remitting

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1: Multiple Sclerosis

Individuals with RRMS who are going to be starting Tysabri as determined by Neurologist as part of clinical care.

Intervention: Drug: Tysabri

Tysabri

Intervention Type DRUG

Participants with RRMS who are planning to begin treatment with Tysabri will be compared to a group of healthy individuals who are matched for age, gender, and education.

Group 2: Healthy Controls

Healthy individuals who are age, gender and education matched to the MS group.

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tysabri

Participants with RRMS who are planning to begin treatment with Tysabri will be compared to a group of healthy individuals who are matched for age, gender, and education.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age between 18-64
* Diagnosed with Relapsing-Remitting Multiple Sclerosis or a healthy volunteer
* If diagnosed with MS: has been newly prescribed Tysabri, but has not yet started taking the medication
* Can read and speak English fluently

Exclusion Criteria

* History of head injury, stroke, seizures, or any other significant neurological event other than MS
* Flare up of MS symptoms within the past month
* History of significant psychiatric illness (for example, bipolar disorder, schizophrenia, or psychosis) or a current diagnosis of Major Depressive Disorder
* Pacemaker or other implanted electrical device, brain stimulator, aneurysm clip (metal clips on the wall of a large artery), metallic prostheses (including metal pins and rods, heart valves, and internal hearing aids \[cochlear implants\]), permanent eyeliner, implanted delivery pumps, or shrapnel fragments
* Left-handed.
* Not able to have an MRI
Minimum Eligible Age

18 Years

Maximum Eligible Age

64 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

St. Barnabas Medical Center

OTHER

Sponsor Role collaborator

Kessler Foundation

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

John DeLuca, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Kessler Foundation

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kessler Foundation

West Orange, New Jersey, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Nancy Moore, M.A.

Role: CONTACT

19733248450

Angela Smith, M.A.

Role: CONTACT

19733248448

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Nancy Moore, MA

Role: primary

973-324-8450

Angela Smith, MA

Role: backup

19733248448

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

US-TYS-11640

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

FOCUS Fatigue Outcome in Copaxone USers
NCT00267319 COMPLETED PHASE4
Fatigue in MS: From Invisible to Measurable
NCT07182903 NOT_YET_RECRUITING
Tysabri Observational Program
NCT00493298 COMPLETED